PACIFIC EDGE LIMITED (PEB)

---

AI Coverage Rating: Active

ASX AI Signals has generated 4 signal for PEB during the last 90 days, indicating active trading activity and ongoing AI monitoring

Latest PEB Signals
18/05/2026	BUY
17/05/2026	BUY
16/05/2026	BUY
PEB Share Price
Current Price	$0.235
52 Week High	$0.260
52 Week Low:	$0.085
Trading at (% of 52 Week High)	90.38%

Business Overview

Pacific Edge Limited (ASX: PEB) is a molecular diagnostics company that develops and commercializes non-invasive tests for the early detection of cancer. Their primary focus is on urine-based tests for bladder cancer and other urological cancers. The company operates in New Zealand, the United States, and other international markets.

ASX Sector Overview

Sector:   Pharmaceuticals, Biotechnology & Life Sciences

The Pharmaceuticals, Biotechnology & Life Sciences sector on the ASX includes companies involved in the development, production, and commercialization of drugs, medical devices, and biotechnology products. This sector covers activities such as research and development of new medicines, genetic testing, and innovative healthcare technologies. Companies often work on treatments for diseases, including cancer, infectious diseases, and chronic conditions. The sector plays a crucial role in advancing medical science and improving patient care through innovation.

Latest AI Recommendation

The BUY signal for PACIFIC EDGE LIMITED (PEB) is supported by current positive momentum and valuation metrics, but tempered by market volatility and sector-specific risks.

Latest  PACIFIC EDGE LIMITED(PEB)   News